Stereotactic body radiotherapy as a primary treatment for spinal metastasis: a single institution experience

被引:2
|
作者
Yeung, Wui Ming [1 ]
机构
[1] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
关键词
Spinal metastasis; stereotactic body radiotherapy (SBRT); local control (LC); toxicity; prognostic factors; RADIATION-THERAPY; PAIN FLARE; RADIOSURGERY; MANAGEMENT; REIRRADIATION; COMPRESSION; INSTABILITY; CONSENSUS; DISEASE;
D O I
10.21037/apm-19-131
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: To investigate the clinical outcome including efficacy and safety of stereotactic body radiotherapy (SBRT) in management of spinal metastasis. Methods: Between 2010 and 2017, 26 patients with 32 metastatic spine lesions treated with SBRT were retrospectively reviewed. Local control (LC), overall survival (OS), prognostic factors and toxicity were analyzed. Results: There were 15 female and 11 male patients (median age, 62 years; range 27 to 88 years). 32 metastatic spine lesions were treated with SBRT. The most frequent lesions treated were metastatic tumours of the lung (n=19), other primary histologies were prostate (n=4), breast (n=3), sarcoma (n=2), hepatocellular carcinoma (n=1), renal cell carcinoma (n=1), stomach (n=1), nasopharyngeal carcinoma (n=1). Thoracic spine was the most common site treated (n=18), followed by lumbosacral spine (n=12) and cervical spine (n=2). The most common dose fractionation used was 24 Gy in 3Fr. The median EQD2/10 Gy was 36 Gy (range, 34.7-59.7 Gy). The median planning target volume (PTV) was 50 cc (range, 10.4-194 cc). The median follow up was 23.4 months (range, 3-103 months). For the entire cohort, local tumour control (LC) at 1 year and 2 years were 83% and 71% respectively. The median OS was 30.6 months. The OS at 1 year and 2 years were 88% and 59% respectively. On univariate analysis for OS, presence of visceral metastases (HR 11.13, P=0.001), uncontrolled primary disease (HR 4.57, P=0.02) and presence of more than 3 vertebral metastasis (HR 5.50, P=0.04) were corelated with worst outcomes. On multivariate analysis for OS, only presence of visceral metastasis remained significant (HR 23.99, P=0.002). Acute toxicity mainly pain flare occurred in 16% of the treated lesions that can be managed with analgesics and steroid. Other adverse events were rare and no radiation induced myelopathy reported. Conclusions: This study reports SBRT is a safe and effective treatment for spinal metastasis. Prognostic factors were identified to guide patient selection that would benefit from this treatment.
引用
收藏
页码:4467 / 4477
页数:11
相关论文
共 50 条
  • [1] Stereotactic body radiotherapy for painful spinal metastases: a decade of experience at a single institution
    Chou, Kuan-Nien
    Park, David J.
    Hori, Yusuke S.
    Persad, Amit R.
    Chuang, Cynthia F.
    Emrich, Sara C.
    Ustrzynski, Louisa
    Tayag, Armine
    Kumar, Kiran A.
    Usoz, Melissa
    Mendoza, Maria
    Rahimy, Elham
    Pollom, Erqi
    Soltys, Scott G.
    Lo, Cheng-Hsiang
    Chang, Steven D.
    JOURNAL OF NEUROSURGERY-SPINE, 2024, 41 (04) : 532 - 540
  • [2] Lung metastasis treatment with Stereotactic Body Radiation Therapy: a single institution experience
    Costa, S.
    Sousa, F.
    Leite-Silva, P.
    Gomes, D.
    Sousa, O.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1305 - S1306
  • [3] Stereotactic ablative body radiotherapy for the treatment of oligometastases: a single-institution experience
    Murphy, G. A.
    Elbeltagi, M.
    LUNG CANCER, 2018, 115 : S57 - S58
  • [4] Stereotactic Ablative Radiotherapy for non-spinal bone metastasis. A single institution experience
    Acosta Rojas, A.
    Nunez, M.
    Montero-Luis, A.
    Sanchez-Saugar, E.
    Hernando-Requejo, O.
    Ciervide-Jurio, R.
    Lopez-Gonzalez, M.
    Garcia-Aranda, M.
    Valero-Albarran, J.
    Rubio-Rodriguez, M. C.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S877 - S878
  • [5] Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
    Paul, S.
    Palkonda, V. A. R.
    Kashyap, L.
    Bhattacharya, K.
    Upadhyay, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Stereotactic Body Radiotherapy for Spinal Metastases: Clinical Experience in 134 Cases From a Single Japanese Institution
    Ito, Kei
    Ogawa, Hiroaki
    Shimizuguchi, Takuya
    Nihei, Keiji
    Furuya, Tomohisa
    Tanaka, Hiroshi
    Karasawa, Katsuyuki
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2018, 17
  • [7] Stereotactic body radiotherapy for treatment of spinal metastasis: A systematic review of the literature
    McVeigh, Luke G.
    Linzey, Joseph R.
    Strong, Michael J.
    Duquette, Elizabeth
    Evans, Joseph R.
    Szerlip, Nicholas J.
    Jackson, William C.
    NEURO-ONCOLOGY ADVANCES, 2024, 6 : iii28 - iii47
  • [8] STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR ADRENAL METASTASIS: A SINGLE CENTER EXPERIENCE
    Camacho Fuentes, Carlos
    Luna Tirado, Javier
    Morcillo Garcia, Ana B.
    Guzman Gomez, Laura P.
    Diaz Silvera, Claudia M.
    Vasquez Rivas, Walter A.
    Perez Cobos, Marta
    Navarro Ruiz de Adana, Ignacio
    Rodriguez-Ponga, Leticia Del Campo
    Azinovic Gamo, Ignacio
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1936 - S1938
  • [9] Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experience
    Jacob, R.
    McDonald, A.
    Manne, U.
    Reddy, S.
    Vickers, S.
    Heslin, M.
    Baig, K. Kyanam Kabir
    Smith, C.
    Williams, G.
    Ali, A.
    Gbolahan, O.
    Rose, B.
    Everett, A. Ashlyn
    Kasi, A.
    Paluri, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience
    Raman, Srinivas
    Yau, Vivian
    Pineda, Sandra
    Le, Lisa W.
    Lau, Anthea
    Bezjak, Andrea
    Cho, B. C. John
    Sun, Alexander
    Hope, Andrew J.
    Giuliani, Meredith
    CLINICAL LUNG CANCER, 2018, 19 (05) : E803 - E810